REGENXBIO Inc. RGNX

Rank #2095 · Nasdaq · $0.4B market cap

⚠ Going-concern flag — the auditor (PricewaterhouseCoopers LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

33.9

P/E

-1.6

P/B

1.19

ROE

-72.8%

Op. Margin

-280.0%

Debt Ratio

66%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -1.6x, P/B 1.19x. Ranks in the top 57% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -72.8%. Ranks in the top 92% of the universe.

Safety ★★★★☆

Good

Debt ratio 66%. Ranks in the top 28% of the universe.

Growth ★☆☆☆☆

Poor

Revenue decline of 26.1% year over year. Ranks in the top 93% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2015	$0.0B	$-0.0B	$-0.0B	$-0.0B	-78.5	-113
2016	$0.0B	$-0.0B	$-0.0B	$-0.0B	-60.2	-33
2017	$0.0B	$-0.0B	$-0.0B	$-0.0B	-304.9	-60
2018	$0.0B	$-0.1B	$-0.1B	$0.2B	-1423.8	7
2019	$0.0B	$-0.1B	$-0.1B	$0.2B	-730.2	22
2020	$0.2B	$0.1B	$0.1B	$0.2B	40.3	26
2021	$0.0B	$-0.1B	$-0.1B	$0.5B	-422.9	65
2022	$0.2B	$-0.1B	$-0.1B	$0.5B	-77.1	78
2023	$0.5B	$0.2B	$0.1B	$0.4B	34.0	84
2024	$0.1B	$-0.3B	$-0.3B	$0.8B	-233.2	34
2025	$0.1B	$-0.2B	$-0.2B	$0.3B	-280.0	66

← See the full screener